• Source: OphthaliX Inc.
    Cornea/External Disease

    The European Patent Office has issued a patent to Can-Fite BioPharma Ltd. covering Adenosine A3 receptor agonists for the treatment of dry eye disorders including Sjogren's syndrome. It relates to OphthaliX Inc.'s drug candidate CF101. Can-Fite is the parent and majority stockholder of OphthaliX.

    This patent grants OphthaliX exclusive rights for the use of CF101 for the treatment of Sjogren's syndrome in Europe until 2025.

    CF101 is a novel, first in class, small molecule, orally bioavailable drug that has demonstrated efficacy and an excellent safety profile in Phase II clinical studies. In addition to dry eye syndrome, the company is developing CF101 to treat glaucoma and uveitis.